Study of Safety of Elotuzumab Administered Over Approximately 60 Minutes in Combination With Lenalidomide and Dexamethasone for Newly Diagnosed or Relapsed/Refractory Multiple Myeloma Patients

Clinical Research Alliance, Inc., New York

Blue Ridge Cancer Care, Blacksburg

St Francis Hospital, Greenville

Greenville Health System, Greenville

Cancer Specialists Of North Florida, Jacksonville

Baptist Health Medical Group Oncology, Miami

Center For Cancer Care & Research, Lakeland

Investigative Clinical Research Of Indiana, Llc, Indianapolis

Horizon Oncology Research, Inc, Lafayette

Oncology Specialists,S.C, Park Ridge

Highland Oncology Group, Fayetteville

Texas Oncology, Dallas

Baylor Charles A. Sammons Cancer Center, Dallas

Blood & Cancer Center of East Texas, Tyler

Local Institution, Houston

Cancer Centers of South Texas, San Antonio

Texas Oncology-McAllen South Second Street, Weslaco

Rocky Mountain Cancer Centers Llp, Denver

Acrc/Arizona Clinical Research Center, Inc., Tucson

James R. Berenson, MD, Inc., West Hollywood

Wellness Oncology & Hematology, West Hills

California Cancer Associates for Research and Excellence, Encinitas

Loma Linda University Cancer Center, Loma Linda

Compassionate Cancer Res Grp, Fountain Valley

Robert A. Moss, Md Facp, Inc., Fountain Valley

Ventura County Hematology-Oncology Specialists, Oxnard

Comprehensive Blood And Cancer Center, Bakersfield

Pacific Cancer Care, Monterey

Vista Oncology Inc., PS, Olympia